packageOcrelizumab

ocrelizumab

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Ocrelizumab is an anti-CD20 monoclonal antibody used to treat multiple sclerosis. It is authorised in the European Union and is an approved medicine, though it has also been investigated for other conditions such as B cell leukemia.

Summary written by glm-5.3-flash from Wikidata Q2013780 and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:ocrelizumab
ATC codes:L04AG08
DrugBank:DB11988
Wikidata:Q2013780
molar mass:145000 g/mol (Drugs.Common 25.09, not verified)

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown